Takenoyama M, Yoshino I, Eifuku R, So T, Imahayashi S, Sugaya M, Yasuda M, Inoue M, Ichiyoshi Y, Osaki T, Nagashima A, Nomoto K, Yasumoto K
Department of Surgery II, University of Occupational and Environmental Health, Yahatanishi-ku, Kitakyushu, Japan.
Jpn J Cancer Res. 2001 Mar;92(3):309-15. doi: 10.1111/j.1349-7006.2001.tb01096.x.
Cytotoxic T lymphocytes (CTL) against human lung cancer cells are difficult to induce by a conventional method using tumor cell stimulation probably due to an insufficiency of tumor antigens (TA) or costimulatory molecules such as CD80. We, therefore, investigated the potential of CD80-transfected tumor cells as stimulators of the in vitro induction of autologous tumor-specific CTL from regional lymph node lymphocytes in patients with lung cancer. Five non-small cell lung cancer cell lines (two adenocarcinomas, 1 squamous cell carcinoma, 1 large cell carcinoma and 1 adenosquamous cell carcinoma) were established from surgical specimens and were successfully transduced with a plasmid constructed with expression vector pBj and human CD80 cDNA, using a lipofection method. CD80-transfected tumor cells (CD80-AT) significantly augmented the proliferation of autologous lymphocytes from all cases as compared with non-transfected tumor cells (AT). AT-stimulated lymphocytes from 4 out of 5 cases did not show any cytotoxicity against AT; however, lymphocytes stimulated with CD80-AT exhibited substantial cytotoxicity against parental AT in all 5 cases tested. AT-stimulated lymphocytes derived from only one out of 5 cases showed major histocompatibility complex (MHC)-class I-restricted cytokine production in response to AT, while the MHC-class I-restricted responses were found in CD80-AT-stimulated lymphocytes from 4 out of 5 cases. These results indicate that CD80 on tumor cells could be a beneficial costimulatory molecule to elicit CTL against lung cancer, and also show that TA recognized by CTL was frequently expressed on lung cancer cells.
传统的利用肿瘤细胞刺激的方法难以诱导出针对人肺癌细胞的细胞毒性T淋巴细胞(CTL),这可能是由于肿瘤抗原(TA)或共刺激分子(如CD80)不足所致。因此,我们研究了用CD80转染的肿瘤细胞作为刺激物,从肺癌患者区域淋巴结淋巴细胞中体外诱导自体肿瘤特异性CTL的潜力。从手术标本中建立了5种非小细胞肺癌细胞系(2种腺癌、1种鳞癌、1种大细胞癌和1种腺鳞癌),并采用脂质体转染法,用表达载体pBj和人CD80 cDNA构建的质粒成功转导这些细胞系。与未转染的肿瘤细胞(AT)相比,CD80转染的肿瘤细胞(CD80-AT)显著增强了所有病例中自体淋巴细胞的增殖。5例中有4例AT刺激的淋巴细胞对AT没有显示出任何细胞毒性;然而,在所有5例测试病例中,CD80-AT刺激的淋巴细胞对亲本AT表现出显著的细胞毒性。5例中仅1例AT刺激的淋巴细胞对AT有主要组织相容性复合体(MHC)-I类限制性细胞因子产生反应,而5例中有4例CD80-AT刺激的淋巴细胞出现MHC-I类限制性反应。这些结果表明,肿瘤细胞上的CD80可能是引发针对肺癌的CTL的有益共刺激分子,也表明CTL识别的TA在肺癌细胞上经常表达。